
What We're Reading: Shutdown Stirs Pharma Worries; Judge Extends Birth Control Ruling; Providers Walk Tightrope
The pharmaceutical industry is looking for answers as the government shutdown, if it lasts longer, could threaten decisions on highly anticipated new drugs; a federal judge in Philadelphia issued a nationwide injunction that prevents the Trump administration from blocking women’s access to free birth control guaranteed under the Affordable Care Act; providers are trying to strike a balance between informing their patients about the Trump administration’s proposed “public charge” rule while not causing undue concern about their immigration status.
Pharma Worried About Drug Approvals if Shutdown Drags On
Federal Judge Blocks Trump Contraception Rule From Taking Effect Nationwide
"Public Charge" Proposal Forces Healthcare Providers Into Delicate Balancing Act With Patients
The pharmaceutical industry is looking for answers as the government shutdown, if it lasts longer, could threaten decisions on highly anticipated new drugs, according to a STAT analysis. The list includes medicines from Janssen, Sanofi, and Novartis for depression, diabetes, and multiple sclerosis, as well as GlaxoSmithKline’s HIV treatment. FDA Commissioner Scott Gottlieb, MD, has warned the agency only has about 3 more weeks’ worth of funding to draw down. Separately, the FDA may restart inspections of high-risk foods as early as Tuesday, as furloughed inspectors have agreed to come back to work without pay,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.